The "INSIGHT" Trial:

An explorative, single center, open-labeled, phase I study to evaluate the feasibility and safety of intra-tumoral, intra-peritoneal, and subcutaneous injections with IMP321 (LAG-3Ig fusion protein) for advanced stage solid tumor entities

Daniel W. Mueller*§, Thorsten O. Goetze*, Regina Eickhoff§, Alexander Reichart*, Salah-Eddin Al-Batran*§

*(**Authors' affiliation:** *Institute of Clinical Cancer Research (IKF) at Krankenhaus Nordwest, UCT-University Cancer Center, Frankfurt, Germany; §IKF Klinische Krebsforschung GmbH am Krankenhaus Nordwest, Frankfurt, Germany)*

Background

The INSIGHT study focuses on evaluation of the feasibility and safety of intratumoral and intraperitoneal injections of IMP321 (mono-agent) for the treatment of advanced stage solid tumors as well as to generate first efficacy data on such treatment.

In the later stage, patients treated with a SOC therapy will receive additional s.c. injections with IMP321 to explore safety and efficacy of combined SOC+IMP321-therapy.

Methods

This is an explorative, mono-center, open-label, investigator initiated phase I trial consisting of three strata, two of which have recently been opened for recruitment:

In **Stratum A**, patients with solid tumors accessible for repeated injections and biopsies receive biweekly intra-tumoral injections with IMP321 (dose escalation 6-12-24-30mg in first cohort and MTD in consolidation cohort).

In **Stratum B**, patients with additional peritoneal carcinomatosis receive intraperitoneal injections of IMP321 via a catheter (dose escalation 1-3-6-12-30mg in first cohort and MTD in consolidation cohort).

In both cohorts, patients showing a treatment benefit after the last direct injection will be offered a **maintenance treatment** consisting of s.c. IMP321 injections for up to 52 weeks.

IMP321

IMP321 is a soluble form of the LAG-3 T cell surface receptor and represents a highly potent activator of antigen presenting cells (APC). It is a member of a new class of drugs known as "APC activators" (primary mode of action).

Study Scheme



- **Primary endpoint:** Feasibility rate
  (rate of pts. receiving protocol treatment according to planned schedule without occurrence of a DLT)
- **Secondary endpoints:** Safety (AEs / SAEs), ORR, individual PFS, individual OS
- **Translational endpoints:** Immune response in whole blood and tumor tissue

Study is open for recruitment; as of mid-May 2018, 7 pts have been recruited into Stratum A (dose escalation accomplished after 3 pts) and 2 pts have been recruited into Stratum B (dose escalation ongoing).

Outlook

If patients treated in course of this phase I study display immune and clinical responses, this POC data will build the basis to evaluate the safety and efficacy of IMP321 direct injection for treatment of the respective tumor entities in larger sets of patients.

KRANKENHAUS NORDWEST

Study management contact information:

Dr. Daniel Mueller mueller.daniel@khnw.de

Phone: +49 69 7601 4125 Fax: +49 69 7601 3655

EudraCT-No.: 2016-002309-20

clinicaltrials.gov: NCT03252938